Issue link: http://osercommunicationsgroup.uberflip.com/i/668575
C h a i n D r u g s t o r e D a i l y 1 9 S a t u r d a y, A p r i l 1 6 , 2 0 1 6 MALLINCKRODT EXTENDS PARTNERSHIPS FOR RESPONSIBLE USE OF PRESCRIPTION DRUGS Helping prevent prescription drug mis- use is a key focus for Mallinckrodt Pharmaceuticals. In the fall of 2015, the company joined the Community Anti-Drug Coalitions of America (CADCA) to launch a pilot project in Florida aimed at ensuring the safe and effective disposal of prescription med- ications. CADCA is the national member- ship organization representing more than 5,000 coalitions and affiliates working to make America's communi- ties safe, healthy and drug-free. CADCA's mission is to strengthen the capacity of community coalitions by providing technical assistance and training, public policy advocacy, media strategies and marketing pro- grams, conferences and special events. Mallinckrodt donated 40,000 biodegradable home medication inacti- vation disposal pouches that use a patented technology to chemically neutralize prescription drugs and make them safe for disposal. The pouches, manufactured by Verde Technologies, are being given out by local coalitions working to identify best practices in safe use, storage and disposal of med- ications, and then determine if these best practices can be replicated in other communities. "Our coalitions find solutions for their community's problems and serve as a local expert on prescription drug abuse. This project provides us with an opportunity to expand on what we have built and amplify the dialogue surrounding disposal of prescriptions medications," said Mary Elizabeth Elliott, Vice President, Communications, Membership and IT at CADCA. "We are providing 40,000 Floridians a new tool to keep our com- munity safe by practicing home dis- posal." "Through a research part of this project, we can also learn if an indi- vidual's behavior regarding safe use, storage and disposal is more influ- enced by messaging regarding their own, or family safety, safeguarding the community, or protecting the envi- ronment," said Kevin Webb, Director of Advocacy Relations at Mallinckrodt. CADCA and Mallinckrodt share a commitment to expand awareness of the dangers involved with prescription medicine misuse and abuse, and to advance solutions to this growing chal- lenge. For Mallinckrodt, this commit- ment begins with President and Chief Executive Officer Mark Trudeau. In late 2015, CADCA honored Mark with its Humanitarian of the Year Award. The award recognizes Mark's personal commitment to help prevent teen drug use, his support of CADCA's mission and Mallinckrodt's collaborative approach. "More than 4,000 Mallinckrodt employees around the world, like the people at CADCA, work to make lives healthier and safer," Mark said. "Our dedication to provide patient solutions is paired with an equal commitment to work with law enforcement officials, healthcare providers, industry repre- sentatives, policymakers and commu- nity organizations to address the com- plex – and complicated – issues of sub- stance abuse and diversion. To be suc- cessful, we must all work together." "Addressing our nation's sub- stance abuse challenges requires col- laboration and commitment from every sector, including the business c o m m u n i t y , " said CADCA Chairman and Chief Executive Officer Gen. Arthur T. Dean. "Mark Trudeau and Mallinckrodt represent an outstanding partner, working closely with CADCA to address the complex issues of sub- stance abuse and diver- sion." Visit Mallinckrodt Pharmaceuticals at booth #318. For more information, call 800.325.8888 or go to www.mallinckrodt.com. MAYNE PHARMA ANNOUNCES $65M MANUFACTURING, DEVELOPMENT EXPANSION On August 28, 2015, Mayne Pharma Group Limited announced a $65 million expansion of its manufacturing and development operations in Greenville, North Carolina, to support projected growth of US Products and Metrics Contract Services. The investment will fund a new greenfield 126,000 square foot oral-dose commercial manufacturing facility on land owned by the company and adjacent to its existing facility. The investment will more than double U.S. manufactur- ing capacity plus repurpose existing space to significantly expand contract analytical and formulation development services capacity. The new facility will allow Mayne Pharma to expand development, manu- facturing and packaging operations for its generic and branded pharmaceutical products, as well as expand its service offering to Metrics Contract Services (MCS) clients by offering downstream commercial manufacturing services. All U.S. distribution was consolidated to Greenville, including the Montgomery warehouse in September 2015. The expansion includes the introduc- tion of commercial scale capability to manufacture modified-release bead/pel- let products. Mayne Pharma currently has seven modified-release products in its pipeline targeting markets with sales greater than $3.5 billion of which three are filed with the FDA. In addition, significant new capacity will be created to manufacture highly potent products, which require special- ized facilities to safely handle them. The company currently has four high potent products targeting markets with sales greater than $2 billion in its pipeline, including Dofetilide capsules, the com- pany's first product eligible for 180-days exclusivity as part of the FDA 'paragraph IV' filing process. Mayne Pharma's Chief Executive Officer, Scott Richards, said, "This invest- ment will ensure we have the internal capacity and capability to support the sustained growth in demand we are expe- riencing in MCS, unconstrained commer- cialization of the expanding pipeline of products under development and the growth in market share we expect from our on-market products. "Once operational, the company will be able to take on new and larger proj- ects, and especially those that leverage our drug-delivery technologies and potent drug handling expertise. The com- pany will also be able to bring manufac- turing in-house for select modified- release products in the pipeline, increas- ing the economic benefit that flows to Mayne Pharma. "Mayne Pharma will considerably strengthen its leadership position in oral drug delivery following the completion of the investments. With a tripling of fluid bed processing capability across our manufacturing net- work, the company will have greater flexibility to expand its modified-release product portfolio and support key exist- ing product franchises including Doxycycline, Morphine Sulphate and Erythromycin." Construction at the Greenville facili- ty began in September 2015 and is expected to be operational in 2018. The company coordinated with local and state governments of North Carolina, and eco- nomic development agencies and secured funding and incentives to support this capital expansion of up to $2.7 million. Mayne Pharma Group Limited (Mayne Pharma) is an ASX-listed spe- cialty pharmaceutical company that develops and manufactures branded and generic products, which it distributes globally, either directly or through distri- bution partners. For more information, visit www.mayne pharma.com or call 800.344.8661.